Free Newsletter
Novartis cancer med combats lymphoma
Free newsletter via e-mail
Tools
The Novartis kidney-cancer remedy Afinitor cut tumor size by 50 percent or more in a third of lymphoma patients in a mid-stage trial; the Swiss drugmaker has started a late-stage trial to evaluate disease-free survival in patients with that disease. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: